Your store. Home page title

Welcome to our store

Online shopping is the process consumers go through to purchase products or services over the Internet. You can edit this in the admin site.

If you have questions, see the Documentation, or post in the Forums at nopCommerce.com

Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component

$199.00 $149.00

28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00

Triple monoamine reuptake inhibitor (TRI) potently inhibiting presynaptic reuptake of serotonin, norepinephrine, and dopamine with IC₅₀ values: NET 1.7-3.2 nM, SERT 11 nM, DAT 8.0-65 nM
Produces approximately twice the weight loss of currently marketed anti-obesity medications; Phase II trials: 9-11% body weight reduction over 24 weeks at therapeutic doses (0.5-1.0 mg)
FDA orphan drug designation for Tesomet (tesofensine + metoprolol) in Prader-Willi syndrome (March 2021) and hypothalamic obesity (July 2021); exceptionally long half-life (~9 days) enabling once-daily dosing

$170.00

Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

$36.40